课题基金 / 基金详情

Illuminating Function of the Understudied Druggable Kinome

Illuminating Function of the Understudied Druggable Kinome
正在研究的可药物激酶组的照明功能
批准号:
9762097
负责人:
GARY L. JOHNSON
金额:
$226.6万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2023-08-31
关键词:
AlgorithmsAnabolismArthritisAttentionBiochemicalBiologicalBiological AssayBiological ProcessCell LineCell physiologyCellsChemicalsChronic Obstructive Airway DiseaseClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCollectionComplementComputational algorithmCystic FibrosisDataData AnalysesDevelopmentDiabetes MellitusDiseaseDown-RegulationDrug TargetingEngineeringEnsureFAIR principlesFoundationsFundingGene ExpressionGenerationsGenesGeneticGoalsHealthHomeostasisHumanImageIndividualInformation Resources ManagementKnowledgeLibrariesLigandsLightLinkLogicMachine LearningMass Spectrum AnalysisMeasurementMeasuresMediatingMetadataMethodsModelingMolecularMonitorMorphologyMutatePharmaceutical PreparationsPhenotypePhosphotransferasesPlayPrecision Medicine InitiativeProductionProteinsProteomicsReactionReagentReporterReporter GenesResearchResearch PersonnelResolutionResourcesRoleSignal TransductionSignal Transduction PathwaySiteSupervisionTechnologyTestingTherapeuticTissuesTumor TissueUnited States National Institutes of HealthUp-RegulationValidationbasecell typecellular imagingclinically significantcomputerized toolsdata resourcedesignhuman diseasehuman modelinformatics toolinnovationinsightinteroperabilitykinase inhibitorknockout geneknowledge basemetabolic profilemetabolomicsnew therapeutic targetnovelnovel therapeuticsphosphoproteomicsprogramsprotein protein interactionscreeningsmall moleculesmall molecule inhibitorstable isotopestructural genomicstherapeutic developmenttherapeutic targettooltranscription factortranscriptome sequencingunsupervised learning

项目摘要

项目成果

GARY L. JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Kinases are among the most important drug targets and clinically significant kinase inhibitors have been developed for multiple diseases. A subset of kinases, the understudied dark kinases (DKs), have received little or no attention because foundational data on their biochemical and biological functions is not available. This proposal will collect such data by perturbing DKs genetically and with small molecules and then measuring the cellular consequences using multiplex proteomic, gene expression, metabolomic and imaging assays. A subset of DKs with potential links to human disease will be intensively studied as a means to qualify new therapeutic drug targets. Data collected in this project will be aggregated with existing information from previous NIH-funded large-scale structural and genomic projects to create a Dark Kinase Knowledgebase (DKK) that provides gene-by-gene and network-level information on the dark kinome and its interaction with other signal transduction and regulatory networks. Close coordination with the NIH LINCS project will ensure data interoperability and make efficient use of informatics tools. The DKK will be developed in collaboration with the IDG Knowledge Management Center (KMC), adhere to standards for Findable, Accessible, Interoperable and Reusable (FAIR) data, and be accessible to human users and machines (via an API). Commercially available DK reagents be validated and extended with new genetic and chemical tools provided to the Resource Dissemination Center (RDOC). The overall approach will be iterative, with simpler methods applied first (e.g. simple gene knockout) and more sophisticated methods subsequently (e.g. stable CRIPSRa/i) pursued by an interdisciplinary team of chemists, computational biologists, mass spectroscopists and pharmacologists working on five linked aims. Aim 1 will develop a computational algorithm for prioritizing DKs, develop and maintain the DKK, and perform network-level analysis on the kinome using supervised and unsupervised machine learning. Aim 2 will measure kinase abundance in normal and perturbed cells using parallel reaction monitoring with stable isotope dilution (PRM-SID) and RNASeq and data analyzed using network inference tools to provide insight into dark and light kinome in diverse cell types. Aim 3 will perturb DKs with genetic tools such as CRIPSR/Cas9-mediated gene knockout, CRIPSRa/i to induce more subtle-up and down regulation and inducible gene inaction. The impact on cell fate, morphology and signal transduction will then be determined using PRM-SID, phosphoproteomics, RNASeq, gene reporter assays, metabolomics profiling and highly multiplex single-cell imaging. Aim 4 will extend DK analysis to small molecule inhibitors by carefully profiling existing drugs against DKs and by designing and synthesizing new chemical ligands. Aim 5 will involve collaboration with other investigators to assay the expression and function of DKs in primary human cells and tissues relevant to the NIH Precision Medicine Initiative. All aims will be pursued in parallel for a progressively expanding resource of data and tools for continued study of DKs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Illuminating Function of the Understudied Druggable Kinome
Illuminating Function of the Understudied Druggable Kinome
Illuminating Function of the Understudied Druggable Kinome
The adaptive kinome in pancreatic cancer
海外基金